BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
Rhea-AI Sentiment
(Very Positive)
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. granted six newly-hired employees stock options and restricted stock units as inducements for joining the company. The options and RSUs total 43,975 and 30,625 shares respectively, with an exercise price of $5.08 per share. Vesting occurs in four equal annual installments starting on the one-year anniversary of the grant date.
  • None.
  • None.

RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 43,975 shares, and restricted stock units (RSUs) covering an aggregate of 30,625 shares, of BioCryst common stock. The options and RSUs were granted as of March 29, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $5.08 per share, which is equal to the closing price of BioCryst common stock on March 28, 2024, the last trading date prior to the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn.


John Bluth
+1 919 859 7910

BioCryst Pharmaceuticals, Inc. granted a total of 43,975 stock options and 30,625 restricted stock units to the newly-hired employees.

The exercise price per share for the stock options granted by BioCryst Pharmaceuticals, Inc. is $5.08.

The options and RSUs granted by BioCryst Pharmaceuticals, Inc. vest in four equal annual installments starting on the one-year anniversary of the grant date.
Biocryst Pharmaceuticals Inc.


BCRX Rankings

BCRX Latest News

BCRX Stock Data

Biological Product (except Diagnostic) Manufacturing
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing

About BCRX

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.